Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ParadigMM-1B AMG 701 With or Without Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
jRCT2080225233Phase 2Terminated
- Sponsor
- Amgen
- Start
- Jun 2020
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of pavurutamab in multiple myeloma (MM) (3 arms), sponsored by Amgen. Primary endpoints: Safety and tolerability of AMG 701 (with or without pomalidomide and dexamethasone), Pharmacokinetics of AMG 701 and 2 more. Started Jun 2020; status: terminated.
02
Drugs
pavurutamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2080225233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225233.